apr-246
Showing 1 - 9 of 9
High-grade Serous Ovarian Cancer Trial in Belgium, Spain, United Kingdom (APR-246, Pegylated Liposomal Doxorubicin Hydrochloride
Completed
- High-grade Serous Ovarian Cancer
- APR-246
- Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
-
Gent, Belgium
- +11 more
Jul 19, 2022
Oesophageal Carcinoma Trial in Australia (APR-246)
Terminated
- Oesophageal Carcinoma
- APR-246
-
Clayton, Victoria, Australia
- +4 more
Dec 10, 2021
Myeloid Malignancy Trial in United States (APR-246, Venetoclax, Azacitidine)
Completed
- Myeloid Malignancy
- APR-246
- +2 more
-
New Haven, Connecticut
- +7 more
Jan 18, 2022
Acute Myeloid Leukemia or MDS Trial in United States (APR-246)
Completed
- Acute Myeloid Leukemia or Myelodysplastic Syndromes
- APR-246
-
Tampa, Florida
- +6 more
Jan 18, 2022
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Tumor Trial in United States (APR-246, Azacitidine)
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 Trial in Worldwide (APR-246, Carboplatin and
Completed
- Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
- APR-246
- Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
-
Los Angeles, California
- +54 more
Sep 20, 2022
Myelodysplastic Syndrome With Gene Mutation, Acute Myeloid Leukemia With Gene Mutations, Myeloproliferative Tumor Trial in
Unknown status
- Myelodysplastic Syndrome With Gene Mutation
- +3 more
- APR-246
- Azacitidine
-
Lille, France
- +6 more
Jan 29, 2020
Hematologic Tumors, Prostatic Tumors Trial in Sweden (APR-246)
Completed
- Hematologic Neoplasms
- Prostatic Neoplasms
- APR-246
-
Göteborg, Sweden
- +5 more
Jul 29, 2019